ZLDPF (Zealand Pharma AS) COGS-to-Revenue : 0.05 (As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma AS COGS-to-Revenue?

Zealand Pharma AS's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.06 Mil. Its Revenue for the three months ended in Dec. 2024 was $1.27 Mil.

Zealand Pharma AS's COGS to Revenue for the three months ended in Dec. 2024 was 0.05.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Zealand Pharma AS's Gross Margin % for the three months ended in Dec. 2024 was 95.44%.

Zealand Pharma AS COGS-to-Revenue Historical Data

The historical data trend for Zealand Pharma AS's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS COGS-to-Revenue Chart

Zealand Pharma AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.10

0.06

0.13

Zealand Pharma AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial															0.60	0.31	0.28	-1.50	0.05

Zealand Pharma AS COGS-to-Revenue Calculation

Zealand Pharma AS's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.105	/	8.802
	=	0.13

Zealand Pharma AS's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.058	/	1.272
	=	0.05

Zealand Pharma AS (OTCPK:ZLDPF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Zealand Pharma AS's Gross Margin % for the three months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.058 / 1.272
	=	95.44 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Zealand Pharma AS COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (OTCPK:ZLDPF) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.